Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Samer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Molecular Diagnosis & Therapy|April 17, 2013
Applications of CYP450 testing in the clinical settingC F Samer, K Ing Lorenzini, V Rollason, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 18, 2014
Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic ModelN Marsousi, Y Daali, S Rudaz, et al.
Clinical Pharmacology and Therapeutics|June 7, 2016
Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approachN Marsousi, C F Samer, P Fontana, et al.
Revue Medicale Suisse|December 4, 2012
[Comparison of four drug interaction screening programs]K Ing Lorenzini, B Reutemann, C F Samer, et al.
Clinical Pharmacology and Therapeutics|April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spotsM Bosilkovska, C F Samer, J Déglon, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Molecular Diagnosis & Therapy|April 17, 2013
Applications of CYP450 testing in the clinical settingC F Samer, K Ing Lorenzini, V Rollason, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 18, 2014
Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic ModelN Marsousi, Y Daali, S Rudaz, et al.
Clinical Pharmacology and Therapeutics|June 7, 2016
Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approachN Marsousi, C F Samer, P Fontana, et al.
Revue Medicale Suisse|December 4, 2012
[Comparison of four drug interaction screening programs]K Ing Lorenzini, B Reutemann, C F Samer, et al.
Clinical Pharmacology and Therapeutics|April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spotsM Bosilkovska, C F Samer, J Déglon, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
Pageof 1